Strict new guidelines lay out a path to heritable human gene editing
By Tina Hesman Saey,
Science News [cites CGS's Katie Hasson]
| 09. 03. 2020
But scientists say making changes in DNA that can be passed on isn’t yet safe and effective
In 2018, Jiankui He (pictured) announced that he had edited genes in embryos to create two baby girls.
Gene editing to make heritable changes in human DNA isn’t yet safe and effective enough to make gene-edited babies, an international scientific commission says. But in a Sept. 3 report, the group laid out a road map for rolling out heritable gene editing should society decide that kind of DNA alteration is acceptable.
The International Commission on the Clinical Use of Human Germline Genome Editing formed after a Chinese scientist announced in 2018 that he had created two gene-edited baby girls, sparking outrage (SN: 11/27/18). In its first official weigh-in on the issue, the group lays out strict scientific criteria that would need to be met before heritable gene editing could be tried clinically. If countries can’t ensure that all of those criteria are met, heritable gene editing shouldn’t be approved, the commissioners say.
Still, some critics charge that even presenting such criteria is premature. The science should wait until society decides whether to allow gene editing that can...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...